Background There is limited evidence on how active commuting is associated with health benefits in developing countries. The aim of this study therefore was to investigate the associations between active commuting and markers of adiposity and cardiometabolic risk in the Chilean adult population.
Introduction
Despite the known protective effects of increased physical activity (PA) against morbidity and mortality, approximately one third of the world's population remains physically inactive. 1, 2 Recently, physical inactivity was cited as the fourth leading cause of non-communicable disease (NCD) mortality, attributable for 5.3 million deaths per year. 3 Global trends, however, indicate prevalence of physical inactivity continues to increase, particularly among low and middle-income countries. 2 In southern Latin American countries, sustained periods of economic growth accompanied by rapid urbanisation of previously rural populations have resulted in paradigm shifts in lifestyle behaviours. 4, 5 Increased access to household appliances, televisions and motorised transportation has been paralleled by decreases in overall levels of PA and increased sedentary behaviour. 5 Subsequently, burden of NCDs has increased in this region, and cardiovascular disease has been the leading cause of mortality over the last 2 decades. 6 Declines in active commuting are suggested to be at least partially responsible for overall declines in population PA, as urban population growth has outpaced infrastructure development and people have shifted to more personalised modes of motorised transport (i.e. driving cars). 7 In 1960, 60% of the Chilean population lived in urban settings, however, in 2015 more than 90% were living in urban cities. 8 This growth in urbanization has been more rapid than in some major developed countries, such as United States and United Kingdom, which showed an increase in urban population from approximately 78 to 83% during these years. 8 Concurrently, the number of cars in Chile has increased from 2 million in 1998 to more than 4.6 million in 2015, while the number of bicycles has increased from 1.1 million to 1.9 million. 9 Active commuting is recommended as a simple way of increasing PA, and recent research has continually reported the health benefits. 10 Investigations into the effects of active commuting on markers of adiposity and cardiometabolic health have reported improved cardiovascular risk profiles and lower prevalence of obesity in those who actively commute.
11-14 A recent study (n > 250 000) reported that active commuting (cycling and walking) was associated with reduced risk of all-cause mortality, CVD and cancer incidence and mortality. 10 Population level observations of active commuting trends are predominantly available in high-income countries, 2 and any observed associations may not be generalizable to other regions. While there is limited evidence of the effects of active commuting in low to middle-income countries, 15, 16 associations between active commuting and prospective health outcomes in southern Latin American countries remain largely unestablished. The aim of this study was therefore to investigate the associations between active commuting and markers of adiposity and cardiometabolic risk in the Chilean adult population.
Methods

Study population
This cross-sectional study was based on data from participants aged ≥15 years from the 2009-10 Chilean National Health Survey (CNHS). The CNHS is a large, nationally representative population-based study of risk factors, dietary status and health conducted every 6 years in Chile. Complex random stratified sampling was used to cover a nationally representative sample based on statistics from the 2002 Chilean National Census, which included strata from administrative regions (county) and urban/rural locations, as described in detail elsewhere. 17 Response rate from the eligible population to the CNHS was 85%. A total of 5276 (97%) people provided data on PA behaviours collected with the Global Physical Activity Questionnaire (GPAQ), version 2. Participants aged <18 years (n = 224) were excluded from the current analysis (results will be reported elsewhere). In addition, 121 participants (3%) with PA data were excluded based on the GPAQ protocol for outlier detection (48% women). Complete data was available for 5155 participants for the present analysis. 17 
Measurements
Socio-demographics
To ensure quality of data collection, standardised protocols were used and nurses and technicians underwent joint training sessions prior to the survey. 17 Socio-demographic data was collected for all participants, including age, gender, education level (primary or <8 years, secondary or between 8 and 12 years, and beyond secondary or >12 years of schooling) and smoking status (non-smoker, ex-smoker or smoker). Dietary intake was measured using a dietary intake questionnaire, which included questions regarding frequency and quantity of consumption of fruit and vegetables and alcohol, whereas sodium intake was measured using urine sample collection. 17 
Anthropometrics
Height was measured to the nearest 0.1 cm using a portable stadiometer and weight was measured to the nearest 0.1 kg using a digital scale (Tanita HD313) with participants removing their shoes and wearing light clothing. 
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Central obesity was defined using waist circumference (WC) (>88 cm for women and >102 cm for men).
Metabolic outcomes
Fasting glucose and haemoglobin A1c (HbA1c) were measured from whole blood collected by trained nurses after an 8 h overnight fast. Analysis of samples was conducted in a certified laboratory facility and has been described in detail elsewhere. 17 T2D was determined via the WHO criteria (fasting plasma glucose ≥126 mg dl −1 ) 19 and/or by selfreport of a pre-existing medical diagnosis and/or in those who reported using glucose lowering medication. Metabolic syndrome was determine according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) as the presence of three or more of the following: waist >102 cm in men, >88 cm in women; triglycerides ≥1.70 mmol/l (150 mg/dL); high density lipoprotein cholesterol (HDL-C) <1.03 mmol/l (40 mg/dL) in men, <1.29 mmol/l (50 mg/dL) in women; blood pressure ≥130/ 85 mm Hg and fasting plasma glucose ≥6.11 mmol/l (110 mg/dL) or self-reported diabetes. 20 
Physical activity
The GPAQ (version 2) was used to measure PA and sedentary behaviour in the CNHS. Developed by the WHO to measure population-level PA behaviours, the GPAQ uses standardised protocols shown to be valid and reliable and adaptable to incorporate cultural and other differences. 21, 22 The GPAQ assesses sedentary behaviour (total time spent sitting) and time spent on active-commuting (PA from travel). For the active commuting domain, participants were asked the following questions: (i) Do you walk or use a bicycle (pedal cycle) for at least 10 min continuously to get to and from places? (Yes, No); (ii) In a typical week, on how many days do you walk or bicycle for at least 10 min continuously to get to and from places? and (iii) How much time do you spend walking or bicycling for travel on a typical day?. These questions were used to derive time spent on active commuting in minutes per day. Total PA was reported as metabolic-equivalent value (MET) using recommendations made by the GPAQ protocol (4-METs was used for transport-related activities and moderate intensity physical activities, whereas 8-METs was used for vigorous intensity physical activities). 23 The GPAQ uses algorithms to categorize weekly PA into two categories: inactive individuals (<600 MET min week −1 ) and active individuals (≥600 MET min
). 23 Sedentary behaviour was derived using the following question: How much time do you usually spend sitting or reclining on a typical day?. 23 
Statistical analysis
Survey-weighted descriptive characteristics are presented as adjusted means with standard deviation (SD) for quantitative variables or as a proportion for categorical variables. Quantitative data was checked for normality using skewness and kurtosis normality tests. For statistical analysis, active commuting was stratified into four categories based on self-reported time spent on active commuting (0: participants who reported not doing active commuting; >30 min a day; 30-60 min a day and >60 min a day).
To investigate the association of active commuting with adiposity and metabolic markers, linear regression analyses were performed. Active commuting was fitted into the model as an ordinal variable (0 = non-active commuters; 1 = <30; 2 = 30-60; and 3 = >60 min day
). The associations of active commuting categories with prevalent obesity, central obesity, T2D and metabolic syndrome were investigated using logistic regression analyses. All models were adjusted for age, sex, education, smoking, leisure PA, sitting time, fruit and vegetable intake, salt and alcohol intake. Metabolic markers were additionally adjusted for BMI.
To account for the differential probability of selection, all outcome estimates (deltas and odds ratio) were weighted using the sample weights provided by CNHS. 17 Statistical analyses were conducted using STATA 14 (StataCorp; College Station, TX). A two-sided α-level of 0.05 was used and all analyses accounted for the complex sample design of CNHS data.
Results
The main characteristics of the participants by active commuting are summarised in Table 1 . In summary, individuals who actively commuted were more likely to have high levels of education and household income, and a slightly higher prevalence of smokers and had a lower prevalence of obesity and physical inactivity compared to the non-active commuting group. Active commuters had a lower BMI and WC, and had higher levels of total PA in comparison to those reporting no active commuting (Table 1) . No major differences were found on time spent on sedentary behaviour and dietary intake patterns between active and non-active commuters.
Overall, there was a significant association of active commuting time with obesity and metabolic markers (Fig. 2) . BMI and WC were −0.56 kg m −2 and −1.12 cm lower in individuals ). Whereas, systolic blood pressure compared to non-active commuters was significantly lower in those accumulating <30, 30-60 and >60 min day −1 (−2.30, −2.72 and −3.80 mm Hg, respectively). No differences were found for total cholesterol, HDL cholesterol, triglycerides and diastolic blood pressure between active commuting groups (Fig. 1) . These associations were independent of sociodemographics, smoking, leisure time PA, sedentary behaviour, dietary behaviour and BMI (when glucose was used as main outcome).
When the association of active commuting time with prevalent obesity, T2D and metabolic syndrome was investigated we found a significant trend for reduced the odds for all these risk factors with increasing active commuting time in comparison to those who reported not actively commuting (Fig. 2) . The odds for overall obesity (BMI > 30.0 kg m , respectively, compared to those who did not report any active commuting. These results were independent of socio-demographics, smoking, leisure time PA, sedentary behaviour, dietary behaviour and BMI (BMI was added when T2D and metabolic syndrome were used as the outcomes) (Fig. 2) . No significant differences were found between active commuting groups (<30, 30-60 and >60 min day ) for any of the health outcomes (P > 0.05).
Discussion
Main finding of this study
The main findings of this study were that active commuting was significantly associated with markers of adiposity and metabolic disease, and prevalence of obesity, T2D and metabolic syndrome. The more time spent on active commuting, the greater the benefits for T2D, WC and systolic blood pressure. Our results reveal that these associations were independent of age, sex, education, leisure time PA, sedentary behaviour, dietary intake and BMI (when adiposity markers were not the outcome). As active commuting has been reported to contribute to overall PA, 24, 25 these results may have important public health implications. Improved provisions for active commuting may facilitate population level health benefits, as it is an inexpensive mode of increasing PA.
What is already known on this topic
The extensive evidence of associations with health for both overall and leisure-time PA 26, 27 contrasts with limited evidence of the effects of non-leisure time PA, such as active commuting, on prospective health outcomes. Previous observational studies have reported similar findings to our own in that active commuting may be associated with lower adiposity and reduced likelihood of obesity. 11, 12, 14 A large cross-sectional analysis of~150 000 people from the UK Biobank cohort reported that mixed-mode commuters (i.e. public transport and active commuters)(men: β coefficient −1.00 kg m 2 [95% CI: −1.14 to −0.87], P < 0.0001; women: −0.67 kg m 2 [−0.86 to −0.47], P < 0.0001) had favourable adiposity profiles compared to car-only commuters, however, the greatest protective benefits of active commuting were observed in those who reported some cycling during their commute (i.e. cycling or walking and cycling) (men: β coefficient −1.71 kg m 2 [95% CI: −1.86 to −1.56], P < 0.0001; women: −1.65 kg m 2 [−1.92 to −1.38], P < 0.0001). 11 We were unable to stratify our data by different modes of active commuting as the GPAQ questionnaire does not include separate questions for cycling, walking or mixed-mode commuting. However, our study provides some evidence that even relatively low levels of active commuting (<30 min day −1 ) may be beneficial for markers of adiposity, compared to people who do not actively commute.
The association between active commuting and incidence of T2D has been previously reported, but remains equivocal. In Finnish adults, >30 min per day active commuting (defined as walking or cycling) reduced risk of T2D by 36% (HR: 0.64 [0.45-0.92]) compared to non-active commuters; and >21 min of walking to work per day reduced the likelihood of T2D in Japanese men by 27% (OR: 0.73 [0.58--0.92]). 28, 29 Despite this, another study of Japanese men reported that walking to work was not associated with incidence of T2D, regardless of how many min day −1 were reported. 13 Our data provides novel evidence of the associations between active commuting and prevalent T2D in a Latin American cohort, and suggests that even low levels of active commuting may be protective against T2D and metabolic syndrome in this population. Other studies conducted in low to middle-income countries (China, India, Mexico, Ghana, Russia and South Africa) 15, 16 have reported that use of active travel for ≥150 min per week is more common in lower socio-economic groups and appears to confer similar health benefits (lower BMI and systolic blood pressure) to those identified in high-income settings. 15, 16 Figure 1 Association of active commuting time with anthropometric and metabolic markers. Data is presented as delta and their 95% CI. Non-active commuters are used as a reference group. Analyses were adjusted for age, sex, education, smoking, leisure PA, sitting time, fruit and vegetable, salt and alcohol intake. Metabolic markers were additionally adjusted for BMI. P-trend indicates the average changes associated with moving one category up on time spent on active commuting.
ACTIVE COMMUTING, OBESITY AND DIABETES
Interestingly, we did not find any association between active commuting and HDL-cholesterol or diastolic blood pressure, which is in disagreement with a previous study were active commuters have shown favourable metabolic health compared to non-active commuters.
14 However, a study conducted in the Chinese population found no association between active commuting time and diastolic blood pressure or HDL-cholesterol in men, although the association was significant for women. 30, 31 To date, there are a limited number of studies which have reported the metabolic benefits of active commuting, as most have focussed on obesity and mortality outcomes. 10, 29, [32] [33] [34] [35] [36] Due to our study not collecting information about the intensity or type of active commuting, we cannot discard a potential confounding effect of these variables. Moreover, our analyses were not stratified by sex, therefore, we do not know whether the lack of association could by driven by men, as previous studies have reported. However, our analysis did not find a significant commuting × sex interaction, so no major differences should be expected within sex.
What this study adds
Data from the 2010 Chilean National Health Survey showed that >60% of the population participated in some form of active commuting. Active commuting may have important contributions to overall PA in this cohort, as 100% of those who reported >30 min day −1 of active commuting were meeting the PA guidelines. This was compared to only 47.8% of those who reported no active commuting. Policies and infrastructure designed to increase population level active commuting presents major opportunities for preventive public health measures in terms of obesity and cardiometabolic risk.
Limitations of this study
The CNHS offered an opportunity to test our research question in a nationally representative sample of the adult Chilean population. Moreover, the inclusion of a wide range of health, demographic and behavioural variables in the dataset allowed for comprehensive adjustment for the effect of confounding factors. However, a key limitation of this study, in common with much of the literature on active commuting and health, is the somewhat crudely quantified exposure. The CNHS participants were asked to give their time spent on transport-related PA, meaning mixed-mode or single-mode journeys (i.e. cycling, walking and public transport) were not captured. Additionally, the cross-sectional nature of this study provides further limitation. As is the case with any observational study, there is the possibility of reverse causation and residual confounding, it might be that people who are unhealthy (i.e. those who are obese or who have diabetes) are unable to travel actively. While we have attempted to minimise residual confounding through adjustment for multiple confounding lifestyle factors, our results do not imply a causative relationship, and further well controlled trials are required to investigate this.
In conclusion, the present data shows a clear association between active commuting and lower adiposity and odds for cardiovascular risk factors, independent of major potential confounding factors. Thus, interventions to increase active commuting could be considered as part of strategies to increase PA levels in the population and therefore reduce the population burden of cardiometabolic disorders.
